These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34281743)

  • 21. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination.
    Machalek DA; Garland SM; Brotherton JML; Bateson D; McNamee K; Stewart M; Rachel Skinner S; Liu B; Cornall AM; Kaldor JM; Tabrizi SN
    J Infect Dis; 2018 Apr; 217(10):1590-1600. PubMed ID: 29425358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fall in human papillomavirus prevalence following a national vaccination program.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Cummins E; Liu B; Bateson D; McNamee K; Garefalakis M; Garland SM
    J Infect Dis; 2012 Dec; 206(11):1645-51. PubMed ID: 23087430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg.
    Latsuzbaia A; Arbyn M; Tapp J; Fischer M; Weyers S; Pesch P; Mossong J
    Cancer Epidemiol; 2019 Dec; 63():101593. PubMed ID: 31499377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
    Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
    Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
    Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
    J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women.
    Wendland EM; Kops NL; Bessel M; Comerlato J; Maranhão AGK; Souza FMA; Villa LL; Pereira GFM
    Vaccine; 2021 Mar; 39(13):1840-1845. PubMed ID: 33674171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
    Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
    PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Human Papillomavirus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women.
    Winer RL; Lin J; Querec TD; Unger ER; Stern JE; Rudd JM; Golden MR; Swanson F; Markowitz LE; Meites E
    J Infect Dis; 2022 Feb; 225(3):422-430. PubMed ID: 34320185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine.
    Schlecht NF; Diaz A; Nucci-Sack A; Shyhalla K; Shankar V; Guillot M; Hollman D; Strickler HD; Burk RD
    JAMA Netw Open; 2021 Aug; 4(8):e2121893. PubMed ID: 34424304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
    Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
    J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
    Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
    Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
    [No Abstract]   [Full Text] [Related]  

  • 32. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program.
    Machalek DA; Chow EP; Garland SM; Wigan R; Cornall AM; Fairley CK; Kaldor JM; Hocking JS; Williams H; McNulty A; Bell C; Marshall L; Ooi C; Chen MY; Tabrizi SN
    J Infect Dis; 2017 Jan; 215(2):202-208. PubMed ID: 27815379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization.
    Liu G; Mugo NR; Brown ER; Mgodi NM; Chirenje ZM; Marrazzo JM; Winer RL; Mansoor L; Palanee-Phillips T; Siva SS; Naidoo L; Jeenarain N; Gaffoor Z; Nair GL; Selepe P; Nakabiito C; Mkhize B; Mirembe BG; Taljaard M; Panchia R; Baeten JM; Balkus JE; Hladik F; Celum CL; Barnabas RV
    AIDS; 2022 Feb; 36(2):257-265. PubMed ID: 34172672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of Lifetime Sexual History on the Prevalence of Genital Human Papillomavirus (HPV) Among Unvaccinated Adults in the National Health and Nutrition Examination Surveys: Implications for Adult HPV Vaccination.
    Rositch AF; Patel EU; Petersen MR; Quinn TC; Gravitt PE; Tobian AAR
    Clin Infect Dis; 2021 May; 72(9):e272-e279. PubMed ID: 32710745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High human papillomavirus prevalence among females attending high school in the Eastern Cape Province of South Africa.
    Mbulawa ZZA; Somdyala NI; Mabunda SA; Williamson AL
    PLoS One; 2021; 16(6):e0253074. PubMed ID: 34143816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
    Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
    Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
    Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
    Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.
    Tabrizi SN; Brotherton JM; Stevens MP; Condon JR; McIntyre P; Smith D; Garland SM;
    J Clin Virol; 2014 Jul; 60(3):250-6. PubMed ID: 24854516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling.
    Deleré Y; Remschmidt C; Leuschner J; Schuster M; Fesenfeld M; Schneider A; Wichmann O; Kaufmann AM
    BMC Infect Dis; 2014 Feb; 14():87. PubMed ID: 24552260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.